While the world’s attention has been rightfully focused on the hope of a breakthrough that will eradicate COVID-19, the private biotech sector has racked up record-breaking investments during the first half of 2020. As much of the economy falls victim to the global threat, venture capital funding…

All across the country small, emerging biotechnology companies are working to solve some of the most important and complex scientific challenges facing the world today. These innovators are racing to develop the medicines and vaccines that will help end the COVID-19 pandemic and ensure we are…

The current COVID-19 pandemic has emphasized the need for a crisis/issues management plan more than ever. Our industry has faced four key areas of disruption including funding challenges, regulatory and commercialization delays, manufacturing and supply chain disruptions and cancellation of medical…

We are living in unprecedented times, as cases of coronavirus (COVID-19) rapidly increase while the world struggles to contain the pandemic. The biotechnology industry has stepped up to help combat this public health threat, working tirelessly to develop potential treatments, diagnostics and…

Day #2 of the BIO CEO & Investor Conference was all about the future. How can we ensure the workforce reflects the diverse demographics of the patients the industry serves? What does the future of biotech investment look like? How can we incentivize innovation? Here are some takeaways from …

The 22nd annual BIO CEO & Investor Forum kicked off today with a Welcome and Update on BIO's 2020 Initiatives on Behalf of the Industry given by Jeremy Levin, CEO of Ovid Therapeutics Chair of the Board of Directors of BIO. The industry was established in 1970’s during an era of bipartisan…

Dr. Benjamin Cowen is the CEO of ImmunoMet, a clinical stage biotech company developing anti-tumor and immune-metabolism therapies. Holding both a PhD and an MBA, Cowen has worked across the spectrum of companies, including large pharma, mid-sized pharma and small venture-backed companies and his…

In a story entitled, “CMS Blames Medicare Part B Hikes on Drug Costs,” writers for Politico Pulse note: “The agency [Centers for Medicare & Medicaid Services] on Friday announced a $9 monthly premium increase and $13 annual deductible hike, but argued that the White House is working to bring…

Supporters of Speaker Pelosi’s drug pricing plan (H.R. 3) claim the bill will discourage the development of so-called “me too” drugs. For example, Rep. Donna Shalala was recently quoted as saying:  “I think it actually will reduce me-too drugs … I think [pharmaceutical companies] are going to…

Since its inception 17 years ago, the BIO Investor Forum has become the premier event where biotech innovators can find investors and strategic partners to advance their company to the next stage in their business life cycle. Over the past two days, more than 340 private equity and public investors…